为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？

Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?

CPNE1 通过 STAT3-TGF-β信号通路促进肝细胞癌的干性并赋予其对 GPC3 CAR-T 细胞治疗的耐药性

CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway.

这些发现表明 CPNE1 是 HCC 进展和免疫抑制的关键调控因子，突显了 CPNE1-STAT3-TGF-轴作为 HCC 中有前景的治疗靶点。

面向实体瘤的工程化 CAR-T 细胞：通过整合设计与临床转化克服微环境

Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation.

靶向 HBsAg 与 GPC3 的单靶点与双靶点 CAR-T 细胞在 HBV 阳性肝细胞癌中平衡安全性与抗肿瘤疗效

Single- and dual-target CAR-T cells targeting HBsAg and GPC3 to balance safety and antitumor efficacy in HBV-positive hepatocellular carcinoma.

CAR-T 细胞的制备与静电表面优化提高肝脏恶性肿瘤疗效

Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies.

CAR-T 结构体的制造条件系统性优化与基于结构的电荷工程协同增强了对肝脏恶性肿瘤的治疗效果，为改善实体瘤 CAR-T 疗法提供了可转化的框架。

用于肝细胞癌的 GPC3 特异性 dnTGFβRII 装甲 CAR-T 细胞

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

第四代抗 GPC3 CAR-T 细胞在肝细胞癌中的体外对比评价

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

肝移植后肝细胞癌复发的 CAR-T 细胞工程化改造

Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation.

双编辑 GPC3 CAR-T 细胞能够抵抗基于他克莫司的免疫抑制，同时限制同种异体反应性，支持其用于肝移植后复发性 HCC。在模块化细胞工程框架中进行序贯、高活力选择，使得能够适应替代性肿瘤靶点和下一代 CAR-T 细胞设计。

肝细胞癌嵌合抗原受体（CAR）T 细胞治疗近期进展综述

A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.

温敏水凝胶局部递送 GPC3-CAR-T 细胞增强肝细胞癌抗肿瘤疗效

Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma.